

## Lab Monitoring for Post-Exposure Prophylaxis (Modified 8/22/05)

Note: For management of specific exposures please see the PEP sections for “Occupational” and “Non-occupational” exposures in the Guideline section. For more details about the PEP protocol, please see the “PEP protocol” in the protocol section.

### I Occupational Exposures

#### a) Non-HMC Employee Occupational Exposures:

	Baseline	2 weeks	6 weeks	12 weeks	24 weeks
<b>All patients</b>	CBC, CMP, HBV, HCV, HIV		HBV*, HCV*, HIV	HCV*, HIV	HCV*, HIV
<b>Women</b>	β-HCG				
<b>On ARVs</b>		CBC, CMP			
<b>If source HCV+ or high risk</b>			HCV RNA, ALT		

\* If source is known to be HBV or HCV negative, follow-up HBV and/or HCV serologies need not be drawn.

#### b) HMC-Employee Occupational Exposures\*\*:

	Baseline	2 weeks	6 weeks	12 weeks	24 weeks
<b>All Patients On ARVs</b>		CBC, CMP			

\*\* All HMC employees should receive the identical lab monitoring as non-HMC employees, but the lab testing other than the 2 weeks toxicity labs will be drawn through employee health (or the ER).

### II Non-occupational Exposures

#### a) Sexual Exposures:

	Baseline	2 weeks	6 weeks	12 weeks	24 weeks
<b>All patients</b>	CBC, CMP, HIV, HBV, HCV, RPR, GC/CT (oral (GC only), rectal, and/or urethral depending on exposure)		HIV, RPR	HIV	HIV
<b>Women</b>	β-HCG				
<b>On ARVs</b>		CBC, CMP			

#### b) Needle Exposures:

	Baseline	2 weeks	6 weeks	12 weeks	24 weeks
<b>All patients</b>	CBC, CMP, HIV, HBV, HCV		HCV***, HIV	HCV***, HIV	HCV***, HIV
<b>Women</b>	β-HCG				
<b>On ARVs</b>		CBC, CMP			
<b>If source HCV+ or high risk</b>			HCV RNA, ALT		

\*\*\* If source is known to be HCV negative, HCV antibody does not need to be drawn during follow-up.